Increasing Access to Biosimilars Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Increasing Access to Biosimilars Act of 2023 is a legislative proposal introduced in the House during the 118th Congress aimed at improving the availability of biosimilar drugs. Biosimilars are medical products highly similar to already approved biologic medicines, potentially offering more affordable treatment options. The bill was referred to the Subcommittee on Health but did not advance further and ultimately expired. No official summary or full text is available to provide detailed provisions or mechanisms.
This bill sought to enhance access to biosimilar drugs but did not progress beyond early committee referral and expired without enactment.
- The bill focuses on the health policy area, specifically related to biosimilar drugs.
- It was introduced in the House of Representatives during the 118th Congress as H.R. 1352.
- The latest recorded action was referral to the Subcommittee on Health on December 17, 2024, with no further legislative movement.
['Patients who may gain access to more affordable biosimilar medications', 'Healthcare providers prescribing biosimilar treatments', 'Pharmaceutical companies involved in biosimilar development and marketing']
['Lack of detailed bill text limits understanding of implementation and enforcement mechanisms', 'Potential cost implications for healthcare systems and insurers are unknown', 'Oversight and regulatory authority provisions are not specified, which could affect policy effectiveness']
The bill was introduced in the context of ongoing efforts to reduce healthcare costs and increase treatment options through biosimilars. It was referred to a relevant subcommittee but did not advance, reflecting either legislative prioritization or other procedural factors. The bill's failure to progress means it did not receive a full congressional review or vote.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in healthcare costs if biosimilar access were increased', 'Possible increased competition in the pharmaceutical market affecting biologic drug pricing', 'Improved patient treatment options through availability of alternative biologic therapies']
The absence of an official summary and full bill text limits transparency and public understanding of the bill's specific provisions and potential impacts. The bill's failure to advance beyond subcommittee referral further restricts oversight opportunities. Future proposals on this topic would benefit from comprehensive documentation to facilitate informed analysis and public engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.